An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats

Fundamental and Clinical Pharmacology

Volumn 25, Issue 5, 2011, Pages 608-618

  Spinnewyn, Brigitte ^a   Charnet, Christelle ^a   Cornet, Sylvie ^a   Roubert, Véronique ^a   Chabrier, Pierre Etienne ^a   Auguet, Michel ^a  

^a IPSEN   (France)

Author keywords

6 OHDA; Dyskinesia; L DOPA; Parkinson's disease; Rat

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ISTRADEFYLLINE; LEVODOPA; OXIDOPAMINE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXIAL DYSTONIA; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DYSKINESIA; DYSTONIA; INVOLUNTARY MOVEMENT; LOCOMOTIVE DYSKINESIA; MALE; NONHUMAN; OROLINGUAL DYSKINESIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENSERAZIDE; BIOLOGICAL ASSAY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PLACEBOS; PURINES; RANDOM ALLOCATION; RATS; REPRODUCIBILITY OF RESULTS; ROTATION; SAMPLE SIZE; SINGLE-BLIND METHOD; SYMPATHOLYTICS;

EID: 80052875420     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00883.x     Document Type: Article

References (43)

1. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology (2000) 55 S13-S20.
2. Rascol O., Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin. Neuropharmacol. (2001) 24 313-323.
3. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology (1998) 50 S17-S25.
4. Rascol O., Brooks D.J., Korczyn A.D. et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord. (2006) 21 1844-1850.
5. Verhagen M.L., Del Dotto P., van den M.P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology (1998) 50 1323-1326.
6. Jankovic J., Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs (2007) 21 677-692.
7. Stocchi F., Tagliati M., Olanow C.W. Treatment of levodopa-induced motor complications. Mov. Disord. (2008) 23(Suppl. 3) S599-S612.
8. Hauser R.A., Shulman L.M., Trugman J.M. et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. (2008) 23 2177-2185.
9. Cenci M.A., Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. (2007) Chapter 9 Unit 9.25.
10. Johansson P.A., Andersson M., Andersson K.E., Cenci M.A. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. (2001) 8 220-239.
11. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. (2006) 96 1718-1727.
12. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. (1998) 10 2694-2706.
13. Picconi B., Centonze D., Hakansson K. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. (2003) 6 501-506.
14. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. (2007) 323 277-284.
15. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. (1996) 16 7206-7215.
16. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. (2002) 15 120-132.
17. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology (2000) 39 777-787.
18. Przedborski S., Levivier M., Jiang H. et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience (1995) 67 631-647.
19. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. (1997) 4 186-200.
20. Henderson J.M., Watson S., Halliday G.M., Heinemann T., Gerlach M. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav. Brain Res. (2003) 139 105-113.
21. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. (2002) 10 165-186.
22. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. (2004) 16 110-123.
23. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 130 1819-1833.
24. Picconi B., Paille V., Ghiglieri V. et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis. (2008) 29 327-335.
25. Lee E.A., Lee W.Y., Kim Y.S., Kang U.J. The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Exp. Neurol. (2003) 184 304-312.
26. Monville C., Torres E.M., Dunnett S.B. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. (2005) 68 16-23.
27. Konitsiotis S., Tsironis C. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon? Behav. Brain Res. (2006) 170 337-341.
28. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. (2002) 3 574-579.
29. Lane E., Dunnett S. Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl). (2008) 199 303-312.
30. Marin C., Rodriguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp. Neurol. (2006) 197 269-274.
31. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. (2006) 23 2669-2676.
32. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav. Brain Res. (2007) 177 150-159.
33. Bezard E., Dovero S., Prunier C. et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. (2001) 21 6853-6861.
34. Blanchet P.J., Allard P., Gregoire L., Tardif F., Bedard P.J. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can. J. Neurol. Sci. (1996) 23 189-193.
35. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. (2000) 47 S2-S9.
36. Fahn S., Oakes D., Shoulson I. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. (2004) 351 2498-2508.
37. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. (2005) 252(Suppl. 4) IV37-IV42.
38. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. (2005) 194 66-75.
39. Dekundy A., Pietraszek M., Schaefer D., Cenci M.A., Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. (2006) Epub. 2006. Jan.25. 69 318-326.
40. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. (1998) 13 798-802.
41. Metman L.V., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. (1999) 56 1383-1386.
42. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. (2000) 15 873-878.
43. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. (2003) 84 1398-1410.